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Introduction
Elevated homocysteine is a risk factor shared 
by neurodegenerative conditions, such as 
cognitive decline (Haan et al. 2007; Tucker 
et al. 2005) and Alzheimer’s disease (Seshadri 
et al. 2002), and cardiovascular diseases 
(CVDs), such as ischemic heart disease and 
stroke (Homocysteine Studies Collaboration 
2002; Wald et al. 2002). Increasing numbers 
of older adults are at risk for these conditions 
because of the unprecedented growth in the 
population of older adults worldwide. Thus, 
understanding and intervening in the deter-
minants of elevated homocysteine concentra-
tions may lessen the public health burden of 
these conditions.
Accumulating epidemiologic and 
experimental research has demonstrated that 
exposure to lead (Pb) increases the risk of 
hypertension (Navas-Acien et al. 2007), and 
recent research has provided strong evidence 
that Pb exposure is a risk factor for ischemic 
heart disease (Jain et al. 2007) and overall 
cardiovascular morbidity and mortality 
(Navas-Acien et al. 2007). More limited 
evidence suggests that exposure to Pb may 
increase plasma homocysteine concentration. 
This is an important consideration for the 
many older adults who have sustained long-
term exposures to high levels of Pb earlier 
in their lives from occupational sources, 
Pb-based paint, and, especially, widespread 
combustion of leaded gasoline. Although 
regulatory actions have dramatically reduced 
these exposures over the last two decades, 
past exposures cannot be undone. Moreover, 
as bone turnover increases with age, Pb that 
has accrued in bone over decades may reenter 
the circulation, resulting in reexposure (Hu 
et al. 2007).
Schafer et al. (2005) proposed that Pb 
may increase homocysteine concentration 
by reacting with sulfhydryl groups on several 
proteins in the homocysteine-processing 
one-carbon metabolism cycle (Figure 1). 
Furthermore, in an in vitro study, methionine, 
an amino acid synthesized from the metabo-
lism of homocysteine (in which folate and 
vitamin B12 are cofactors) reduced oxidative 
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Background: Lead (Pb) exposure may influence the plasma concentration of homocysteine, a 
one-carbon metabolite associated with cardiovascular and neurodegenerative diseases. Little is 
known about the associations between Pb and homocysteine over time, or the potential influence of 
dietary factors.
oBjectives: We examined the longitudinal association of recent and cumulative Pb exposure with 
homocysteine concentrations and the potential modifying effect of dietary nutrients involved in 
one-carbon metabolism.
Methods: In a subcohort of the Veterans Affairs (VA) Normative Aging Study (1,056 men with 
2,301 total observations between 1993 and 2011), we used mixed-effects models to estimate differ-
ences in repeated measures of total plasma homocysteine across concentrations of Pb in blood 
and tibia bone, assessing recent and cumulative Pb exposure, respectively. We also assessed effect 
  modification by dietary intake and plasma concentrations of folate, vitamin B6, and vitamin B12.
results: An interquartile range (IQR) increment in blood Pb (3 μg/dL) was associated with a 
6.3% higher homocysteine concentration (95% CI: 4.8, 7.8%). An IQR increment in tibia bone Pb 
(14 μg/g) was associated with a 3.7% higher homocysteine (95% CI: 1.6, 5.6%), which was attenu-
ated to 1.5% (95% CI: –0.5, 3.6%) after adjusting for blood Pb. For comparison, a 5-year increase 
in time from baseline was associated with a 5.7% increase in homocysteine (95% CI: 4.3, 7.1%). 
The association between blood Pb and homocysteine was significantly stronger among participants 
with estimated dietary intakes of vitamin B6 and folate below (vs. above) the study population 
medians, which were similar to the U.S. recommended dietary allowance intakes.
conclusions: Pb exposure was positively associated with plasma homocysteine concentration. This 
association was stronger among men with below-median dietary intakes of vitamins B6 and folate. 
These findings suggest that increasing intake of folate and B6 might reduce Pb-associated increases 
in homocysteine, a risk factor for cardiovascular disease and neurodegeneration.
citation: Bakulski KM, Park SK, Weisskopf MG, Tucker KL, Sparrow D, Spiro A III, 
Vokonas PS, Nie LH, Hu H, Weuve J. 2014. Lead exposure, B vitamins, and plasma homo-
cysteine in men 55 years of age and older: the VA Normative Aging Study. Environ Health Perspect 
122:1066–1074; http://dx.doi.org/10.1289/ehp.1306931Pb exposure and B vitamins influence homocysteine
Environmental Health Perspectives  •  volume 122 | number 10 | October 2014  1067
stress and related physiological damage in 
Pb-exposed neuroblastoma cells (Chen et al. 
2011). Previous epidemiologic studies have 
reported higher blood Pb concentration—an 
indicator of recent exposure to Pb (half-life 
of Pb in blood is approximately 30 days) 
(Hu et al. 1998)—in association with higher 
plasma homocysteine (Chia et al. 2007; Lee 
et al. 2012; Schafer et al. 2005; Yakub and 
Iqbal 2010). Little is known, however, about 
the potential influence of past and cumulative 
Pb exposures on homocysteine and changes 
in homocysteine over time. Further, to our 
knowledge, there have not been any longi-
tudinal studies of the potential influence of 
the methyl donors—folate and B vitamins—
on the association between Pb and plasma 
homocysteine. If diet can modify the associa-
tion between Pb exposure and homocysteine, 
as suggested by findings from an analysis of 
cross-sectional data from the U.S. National 
Health and Nutrition Examination Survey 
(NHANES) (Lee et al. 2012), this could 
be a critical means for reducing deleterious 
effects of Pb exposure, even after exogenous 
exposure has ended.
Therefore, using an established longitu-
dinal study of older men, we evaluated the 
association between Pb exposure and circu-
lating levels of homocysteine, and the degree 
to which this association is modified by esti-
mated intakes of methyl-donor nutrients/
cofactors (i.e., folic acid, vitamin B12, and 
vitamin B6). We estimated the association 
between recent exposure to Pb, measured 
by blood Pb concentration, and concurrent 
homocysteine concentration. We compared 
associations of recent versus cumulative Pb 
exposures with homocysteine concentration 
using concentrations of Pb measured in blood 
and bone, respectively. Finally, we tested 
whether associations between Pb exposure and 
homocysteine were increased among partici-
pants whose diets were low in methyl-donor 
nutrients compared with other men.
Materials and Methods
Study population. From 1961 to 1970, 2,280 
men in the greater Boston area, 21–81 years 
of age, were enrolled in the Veteran’s Affairs 
(VA) Normative Aging Study (NAS) (Bell 
et al. 1972). All of the men were free of 
known chronic medical conditions at enroll-
ment and were invited to participate in 
health assessments every 3–5 years. Blood 
Pb measurements were begun in 1977, 
and bone Pb measurements were begun in 
1991. Homocysteine assessment began in 
1993. Nearly all homocysteine measure-
ments (> 99%) were made within 30 days 
of a blood Pb measurement. At each study 
visit, self-reported smoking status, medica-
tion use, physical activity, and dietary intake 
were assessed.
Of the 1,218 men with blood Pb 
measurements, 1,056 (99.4%) had at least 
one homocysteine measurement and data on 
key covariates (2,301 repeated observations in 
total). Our analysis of change in blood Pb in 
relation to change in homocysteine included 
the 747 men who had at least two repeated 
measures of blood Pb and concurrent homo-
cysteine (1,830 observations). Of the 851 
individuals with bone Pb measurements, 777 
(91.3%) had homocysteine and key covariate 
data (2,158 observations) and were included 
in our analyses of baseline bone Pb in relation 
to concurrent and subsequent homocysteine. 
Loss to follow-up did not vary by baseline Pb 
level or homocysteine (data not shown).
The human subjects institutional review 
boards at the Harvard School of Public 
Health, the Department of Veterans Affairs 
Healthcare System in Boston, the Brigham and 
Women’s Hospital (Boston, MA, USA), and 
the University of Michigan Health Sciences 
approved the present study. All participants 
provided written informed consent.
Assessment of Pb exposure. We assessed 
participants’ recent exposure to Pb using 
concentration of Pb in whole blood, measured 
via graphite furnace atomic absorption with 
Zeeman background correction. For the 
present study, we used blood Pb concentra-
tions from 1993 to 2011 (up to six measures 
per participant). To assess participants’ 
cumulative exposure to Pb, we measured 
baseline Pb concentrations in two bone sites 
(tibia and patella) via cadmium-109 (Cd109) 
K-shell X-ray fluorescence (KXRF) spectros-
copy using previously described methods (Hu 
et al. 1996). The half-life of Pb in cortical tibia 
bone is approximately 49 years in this study 
population (Wilker et al. 2011). Its half-life in 
trabecular patella bone is shorter, 10–15 years, 
depending on the study population (Hu 
et al. 1998).
Assessment of dietary nutrients. Annual 
average diet was assessed with the semiquanti-
tative Willett Food Frequency Questionnaire 
(FFQ) (van de Rest et al. 2009). The question-
naire assesses usual frequency of consumption 
of 126 foods (on a scale ranging from never to 
≥ 2 times per day) and supplements (no/yes, 
plus the amount). We estimated participants’ 
dietary and supplement intakes of three one-
carbon metabolism nutrients: folate, vitamin 
B6, and vitamin B12. Intakes of vitamins B6 
and B12 were available from all study waves, 
whereas estimates of folate intake were only 
available from wave 2 and onward.
Assessment of plasma homocysteine 
and B vitamins. Fasting blood plasma was 
collected during each clinic visit and frozen 
at –80°C. Samples were analyzed at the 
Jean Mayer U.S. Department of Agriculture 
Figure 1. One-carbon metabolism pathway. Homocysteine can be elevated in conditions of low 
folate, low vitamin B6, or low vitamin B12. The sulfhydryl groups on several proteins, including cysta-
thionine β-synthase, in the one-carbon metabolism pathway are potential sites for interferences by Pb. 
Abbreviations: Ado, adenosine; BHMT, betaine-homocysteine S-methyltransferase; CBS, cystathionine 
β-synthase; DHF, dihydrofolate; DMG, dimethylglycine; Glu, glutamate; Gly, glycine; GSH, glutathione; 
MS, methionine synthase; MT, methyltransferase; MTHFR, methylenetetrahydrofolate reductase; SAH, 
S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate; Zn, zinc. Adapted from 
Bistulfi et al. (2010).
*Indicates putative locations for interference by Pb.
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Human Nutrition Research Center on Aging 
(HNRCA; Boston, MA, USA). Plasma 
concentrations of total homocysteine and 
B vitamins—folate, pyridoxal 5 phosphate 
(PLP, the activated form of vitamin B6), and 
vitamin B12—were measured in fasting blood 
plasma samples via fluorescence detection 
with HPLC at the HNRCA (Araki and Sako 
1987). Homocysteine detection methods 
have been previously described (Tucker et al. 
2005). The coefficients of variation (CVs) 
for the biochemical assays of homocysteine, 
folate, PLP, and vitamin B12 were 4.0%, 
4.3%, 5.0%, and 4.7%, respectively.
Statistical analysis. All analyses were 
performed using R statistical software (version 
2.15.0; R Project for Statistical Computing; 
http://www.r-project.org/). Means ± SD of 
Pb markers and geometric means (GMs) 
[geometric standard deviations (GSDs)] of 
homocysteine concentrations by key covari-
ates were computed. Tests for linear trend 
across categories were assessed by assigning 
integer scores to each ordinal covariate 
category and modeling as an ordinal variable. 
We used analysis of variance tests to compare 
the mean differences of Pb and homocysteine 
concentrations by smoking status.
We performed cross-sectional analyses 
of Pb exposure and homocysteine at each 
individual visit. Using the repeated measures 
of blood Pb exposure and homocysteine, 
we estimated the percentage difference in 
homocysteine per increment in Pb exposure 
measure using multivariable-adjusted linear 
mixed-effects models, with random intercepts, 
of natural log-transformed homo  cysteine 
(Fitzmaurice et al. 2004). We analyzed each of 
the Pb exposure measures separately, modeling 
repeated blood Pb measurements in relation to 
concurrent homo  cysteine, and baseline bone 
Pb measurements in relation to concurrent 
and subsequent homocysteine measurements, 
collectively. We tested for non  linear trends 
using generalized additive models with penal-
ized splines in the mgcv R package; because 
the estimated degrees of freedom for blood 
and bone Pb concentrations were equal to 
1 (i.e., consistent with a linear association 
between Pb and homocysteine), we used 
linear models (Hastie and Tibshirani 1990; 
Wood 2006). All analyses were adjusted for 
a core set of covariates previously associated 
with homocysteine: baseline age (years), time 
since baseline, attained education (< high 
school, ≥ high school degree), smoking status 
(current, former, never; time-varying), alcohol 
consumption (< 2 drinks/day, > 2 drinks/day; 
time-varying), and body mass index [BMI (in 
kilograms per square meter); time-varying] 
(Schafer et al. 2005). We checked for inter-
actions between covariates and time since 
baseline, but including these terms did not 
improve the model fit. We further adjusted 
for intake of methyl-donor nutrients using two 
approaches. First, we adjusted for continuous 
plasma concentrations of PLP, vitamin B12, 
and folate concurrent with homocysteine 
measures. In the second approach, we adjusted 
for continuous FFQ-based estimates of total 
energy intake and energy-adjusted dietary 
intakes (Willett et al. 1997) of vitamin B6, 
vitamin B12, and folate as well as supple-
ment use (quantity per day) of vitamin B6, 
vitamin B12, and folate, reflecting intake over 
the previous year. As a sensitivity analysis, we 
adjusted bone Pb with long-term dietary trend, 
calculated by averaging FFQ estimates of daily 
intake over three or more visits for a subset of 
individuals (n = 221). For a secondary test, we 
restricted blood Pb analyses to individuals who 
had both plasma and dietary nutrient data. 
These analyses contained only 1,221 observa-
tions from 774 participants. As a sensitivity 
analysis, we tested to see whether the associa-
tion between blood Pb and homocysteine was 
mediated by kidney function (as approximated 
by serum creatinine and estimated creatinine 
clearance). Creatinine clearance (in milliliters 
per minute) was estimated using the equation 
[(140 – age) × weight (kg)]/[72 × serum 
creatinine (mg/dL)] (Wu et al. 2003). We 
compared models of core covariates with blood 
Pb alone, creatinine alone, and blood Pb and 
 creatinine  together.
To explore the possibility that the associa-
tion of cumulative Pb dose with homocysteine 
might be mediated through recent exposure 
(e.g., from Pb released into circulation via 
bone resorption), we compared results from 
models of baseline tibia Pb in relation to 
concurrently assessed homocysteine concen-
tration with and without further adjustment 
for blood Pb concentration. We performed 
similar analyses for patella Pb. Although this 
simple approach for assessing mediation is 
problematic in many settings, it can generate 
valid estimates under the following conditions: 
a) both the mediator (in the present study, 
blood Pb) and outcome (homocysteine) are 
continuous and can be modeled using linear 
regression—a condition that was clearly met; 
b) there is no confounding of the mediator–
outcome association (e.g., no common causes 
of homocysteine and bone resorption, which 
increases blood Pb); and c) there is no inter-
action between exposure and mediator (i.e., 
at high bone Pb concentrations, the effect per 
unit increase in blood Pb is no larger or smaller 
than at low bone Pb concentrations) (Kaufman 
et al. 2004). As an analysis of the sensitivity of 
this approach, we also applied a method with 
a formal basis in causal frameworks (Valeri 
and Vanderweele 2013) that estimates the 
total effect of bone Pb on homocysteine along 
with the indirect effect of bone Pb on homo-
cysteine via blood Pb concentration, and the 
direct effect of bone Pb on homocysteine via 
pathways independent of blood Pb concen-
tration (Imai et al. 2010). This procedure, 
the Baron–Kenny procedure with inter-
action term, also quantitatively evaluates the 
impact of inter  action (irrespective of magni-
tude) between the exposure and mediator on 
the findings.
When participants had at least two study 
visits, we examined changes in blood Pb 
concentration over time in relation to concomi-
tant changes in homocysteine. We did this by 
regressing the visit-to-visit change in homo-
cysteine on change in blood Pb concentration 
using the general structure, [homocysteinet – 
homocysteinet – 1] = β0 + β1[blood Pb 
concentrationt – blood Pb concentrationt – 1], 
where t indexes a given visit, t – 1 indexes the 
visit before visit t, and the parameter of interest 
is β1, the difference in visit-to-visit changes 
in homocysteine corresponding to a 1-μg/dL 
greater visit-to-visit change in blood Pb 
concentration (e.g., comparing a visit-to-visit 
increase in blood Pb concentration of 1 μg/dL 
with no change). For these analyses, we used 
linear mixed models to account for correlations 
between repeated dyads of observations from 
the same individuals (e.g., change from wave 1 
to wave 2, change from wave 2 to wave 3). The 
association between change in blood Pb and 
change in homocysteine was not linear; there-
fore, we modeled increases and decreases in 
blood Pb concentrations using separate terms 
(reference: no change in blood Pb concentra-
tion), effectively a piece-wise regression model 
with a breakpoint at [blood Pb concentra-
tiont – blood Pb concentrationt – 1] = 0. We 
adjusted these analyses for time between visits, 
age at the start of the interval, and trajectory in 
smoking status over the interval (i.e., always a 
former smoker, quit smoking, always a smoker, 
began smoking, always a never-smoker). 
Adjusting for additional covariates did not 
change the findings. These analyses involved 
the data of 1,245 visit-to-visit intervals from 
747 participants.
To examine whether past or cumulative 
Pb exposure might influence the long-term 
trajectory of homocysteine concentration with 
age, we compared trajectories in homo  cysteine 
(as percentage change from baseline homo-
cysteine) by tibia bone Pb concentration at 
baseline. To do so, we amended our mixed-
effects linear models for tibia Pb concentra-
tion with a cross-product term between time 
since baseline and tibia Pb concentration. This 
model also contained a cross-product term 
between time and baseline age. The inclusion 
of other time–covariate cross-products did not 
change the results (data not shown).
To compare the association of Pb exposure 
with homocysteine by intake of methyl-donor 
nutrients, we fit models that incorporated all 
observations and included a cross-product 
term between each Pb exposure measure and Pb exposure and B vitamins influence homocysteine
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dichotomous nutrient measure (median, or 
equal to/above vs. below the median). We also 
compared men who were below the median 
for all nutrient measures (n = 517, plasma; 
n = 383, diet) with men above the median 
for all nutrient measures (n = 473, plasma; 
n = 376, diet). In our primary analyses of the 
potential inter  action of blood Pb concentra-
tion with dietary nutrients, we fit models 
stratified according to intake from food and 
then further adjusted for supplement use (yes, 
no), thus treating supplement use as a surro-
gate for confounding by socioeconomic status 
(SES), especially in the stratum of high intake. 
Although dietary supplements make up part of 
the total nutrient intake, use of these supple-
ments is also related to SES, which predicts 
Pb exposure, and can affect dietary choices 
in complex ways (Radimer et al. 2004; Rock 
2007). Median estimated dietary intakes 
of folate and vitamins B6 and B12 were 
343 μg/day, 2.24 mg/day, and 6.19 μg/day, 
respectively. Median plasma nutrient concen-
trations were 11.6 ng/mL folate, 64.1 nmol/L 
B6, and 449 pg/mL B12.
We also tried multiple alternative 
analyti  cal approaches. We stratified analyses 
by supplement use (yes/no) among all partici-
pants, by supplement use (equal to/above 
vs. below the median) restricted to supple-
ment users, and by total intake (dietary and 
supplement). Analyzing supplement data 
entails complex considerations. In addition 
to its patterning by SES, particularly during 
the years of the present study, supplement use 
dramatically increased total nutrient intakes 
(often by an order of magnitude or more), 
yet trials of supplement use in healthy popu-
lations have yielded equivocal findings with 
respect to several health effects (Fortmann 
et al. 2013). To circumvent these complexi-
ties, we also conducted sensitivity analyses that 
were stratified by dietary intake, restricted to 
non supplement  users.
Results
Of the 1,056 men in our study, 55–97 years 
of age at baseline, mean (± SD) concentra-
tions of Pb in blood and tibia bone were 
4.9 ± 2.7 μg/dL and 21.4 ± 13.5 μg/g, respec-
tively (Table 1). The mean (± SD) patella 
Table 1. Blood Pb, tibia bone Pb, and plasma homocysteine concentrations, by key baseline participant characteristics among study participants with data on 
blood Pb and homocysteine concentrations (n = 1,056).
Characteristic
n (%) or 
mean ± SD
Blood Pb (μg/dL)  Tibia bone Pb (μg/g)  Plasma homocysteine (μmol/L)
Mean ± SD p-Valuea Mean ± SD p-Valuea GM (GSD) p-Valuea
Overall value 4.9 ± 2.7 21.4 ± 13.5 10.1 (1.3)
Age (years) 69 ± 7.4
50–65 355 (34) 4.6 ± 2.6 0.03 16.5 ± 9.3 < 0.0001 9.8 (1.4) < 0.0001
66–71 327 (31) 4.9 ± 2.8 21.8 ± 12.3 9.9 (1.3)
72–97 374 (35) 5 ± 2.8 26 ± 16.3 10.7 (1.3)
Education
< High school 80 (8) 5.8 ± 3 < 0.0001 30.2 ± 18.6 < 0.0001 9.8 (1.3) 0.9
High school 303 (29) 5.2 ± 2.9 24.7 ± 15.9 10.2 (1.4)
Some college 288 (27) 4.8 ± 2.7 20.3 ± 11 10.1 (1.3)
College degree 202 (19) 4.5 ± 2.3 18.9 ± 11.3 9.9 (1.3)
> College degree 183 (17) 4.4 ± 2.8 17 ± 9.4 10.2 (1.3)
Smoking status
Never 296 (28) 4.8 ± 3 0.1 20 ± 13.7 0.002 9.8 (1.3) 0.005
Former 698 (66) 4.8 ± 2.6 22 ± 13.6 10.1 (1.3)
Current 62 (6) 5.8 ± 3.2 22.1 ± 11.5 11.2 (1.3)
Alcohol consumption (drinks/day)
< 2 834 (79) 4.6 ± 2.7 < 0.0001 21.4 ± 13.9 0.5 9.9 (1.3) < 0.0001
≥ 2 222 (21) 5.7 ± 2.9 21.2 ± 12.1 10.8 (1.4)
BMI (kg/m2) 28 ± 3.9
< 25 216 (21) 4.9 ± 2.8 0.5 21.4 ± 11.5 0.3 10.1 (1.3) 0.9
25 to < 30 574 (54) 4.8 ± 2.7 21.8 ± 14.3 10.1 (1.3)
≥ 30 266 (25) 4.8 ± 2.8 20.4 ± 13.3 10.1 (1.3)
Plasma vitamin B6 (nmol/L) 87.5 ± 87.2
< 61.8 561 (53.1) 5.2 ± 2.9 < 0.0001 23.0 ± 14.2 < 0.0001 10.8 (1.3) < 0.0001
≥ 61.8 483 (45.7) 4.4 ± 2.5 19.3 ± 12.4 9.4 (1.3)
Plasma vitamin B12 (pg/mL) 466.4 ± 222
< 431 566 (53.6) 5.1 ± 2.8 < 0.0001 21.5 ± 12.0 0.5 10.8 (1.3) < 0.0001
≥ 431 469 (44.4) 4.5 ± 2.6 21.1 ± 14.9 9.3 (1.3)
Plasma folate (ng/mL) 11 ± 7
< 9.8 621 (58.8) 5.2 ± 2.8 < 0.0001 21.5 ± 12.9 0.1 10.7 (1.3) < 0.0001
≥ 9.8 405 (38.4) 4.4 ± 2.6 20.9 ± 13.8 9.3 (1.3)
Dietary vitamin B6 (mg/day) 2.3 ± 0.9
< 1.8 254 (24) 5.4 ± 2.8 < 0.0001 22.8 ± 14.7 0.2 10.6 (1.3) 0.0002
1.8 to < 2.2 255 (24) 4.9 ± 2.8 21 ± 12.4 10.1 (1.3)
2.2 to < 2.8 246 (23) 4.7 ± 2.7 21 ± 13.5 10.2 (1.3)
≥ 2.8 252 (24) 4.4 ± 2.6 21 ± 13.9 9.6 (1.3)
Dietary vitamin B12 (μg/day) 7.9 ± 5.5
< 4.4 252 (24) 5 ± 2.6 0.9 22.1 ± 13.8 0.4 10.4 (1.3) 0.2
4.4 to 6.2 253 (24) 4.7 ± 2.8 20.1 ± 12.8 10.1 (1.3)
6.2 to 9.0 250 (24) 4.8 ± 2.8 20 ± 12.6 9.8 (1.3)
≥ 9.0 252 (24) 5 ± 2.8 23.4 ± 14.9 10.2 (1.3)
Dietary folate (μg/day)b 374.8 ± 178.1
< 248.5 135 (18) 4.5 ± 2.8 0.001 21.7 ± 11.7 0.2 9.9 (1.3) 0.7
248.5 to 327.3 134 (18) 4.0 ± 2.4 21.1 ± 13.1 10.3 (1.3)
327.3 to 440 134 (18) 4.0 ± 2.1 19.3 ± 19.3 10.1 (1.4)
≥ 440 134 (18) 3.6 ± 1.7 19.6 ± 19.6 9.9 (1.3)
aCalculated using a test for linear trend across ordinal categories of nonmissing data. bCalculated at visit 2, due to missing data at visit 1.Bakulski et al.
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Pb concentration was 30.6 ± 20.1 μg/g (data 
not shown). At baseline, the GM (GSD) 
homocysteine concentration was 10.1 (1.3) 
μmol/L. Baseline plasma concentrations of 
vitamin B12 (98–4,081 pg/mL) and folate 
(1–69 ng/mL) were also similar to those of 
U.S. men > 60 years of age (Pfeiffer et al. 
2005). Baseline plasma PLP (vitamin B6) 
nutrient concentrations ranged from 5 to 
995 nmol/L. The U.S. recommended daily 
allowance (RDA) for folate is 400 μg/day, 
and 279 participants (62.6%) consumed less 
than the RDA from estimated diet alone. 
RDAs of vitamin B6 and B12 are 1.7 mg/day 
and 2.4 μg/day, respectively. In our popula-
tion, 233 (22.1%) consumed less vitamin B6, 
and 47 (4.5%) consumed less vitamin B12, 
than the RDA from estimated diet alone.
At baseline, homocysteine was positively 
correlated with blood Pb, tibia bone Pb, 
and patella bone Pb concentrations (respec-
tively, Pearson’s r = 0.27, 0.15, and 0.15; 
all p < 0.001). Pb concentrations were lower 
among men who were younger and had more 
education, higher plasma concentrations of 
the three nutrients, and higher dietary intakes 
of vitamins B6 and folate (Table 1).
Association of recent Pb exposure 
with homocysteine. Recent exposure to Pb, 
measured by blood Pb concentration, was 
significantly associated with concurrent 
plasma homocysteine concentration (Table 2). 
After adjusting for baseline age, time since 
baseline, education, alcohol, smoking, and 
BMI, an interquartile range (IQR) incre-
ment in blood Pb (3 μg/dL) was associated 
with 6.3% higher homocysteine (95% CI: 
4.8, 7.8%). This association diminished 
slightly with further adjustment for plasma 
concentrations of the three methyl-donor 
nutrients (5.5% higher; 95% CI: 4.0, 6.9%), 
but not with further adjustment for dietary 
intakes of these nutrients plus total energy 
consumption (6.5%; 95% CI: 4.3, 8.8%). 
These associations may have varied at least 
in part because they were based on different 
subsets of observations due to missing nutrient 
exposure data. When we restricted the blood 
Pb analyses to individuals with both plasma 
and dietary nutrient data, the estimated asso-
ciation between blood Pb concentration and 
homocysteine varied by < 10% across the core 
model (6.4%; 95% CI: 4.3, 8.5%), plasma 
model (5.8%; 95% CI: 3.7, 7.9%), and 
dietary model (5.9%; 95% CI: 3.8, 8.1%). 
For comparison, results from the model that 
included terms for the core covariates and 
current blood Pb concentration indicated 
that homocysteine concentrations were 5.7% 
higher, on average, in association with a 
5-year passage of time since baseline (95% CI: 
4.3, 7.1%), and 13% higher (95% CI: 
–0.2, 28.1%) in current smokers compared 
with never-smokers.
In additional sensitivity analyses that were 
further adjusted for creatinine clearance (an 
intermediate marker of kidney function), 
the association of an IQR increment in 
blood Pb concentration with higher homo-
cysteine remained significant (6.3%; 95% CI: 
4.8, 7.8%).
Association of cumulative Pb exposure 
with homocysteine. Higher cumulative 
exposure to Pb, measured by baseline tibia 
bone Pb concentration, was also significantly 
associated with elevated plasma homocysteine 
(Table 2). After adjusting for the core group 
of covariates, an IQR increment in tibia bone 
Pb concentration (14 μg/g) was associated 
with 3.7% higher homocysteine (95% CI: 
1.7, 5.6%). Further adjustment for plasma 
and dietary methyl-donor nutrients did not 
alter this finding. The corresponding associa-
tions with homocysteine per IQR increase in 
baseline patella Pb concentration (21 μg/g) 
were consistent with those estimated per IQR 
increase in tibia Pb concentration (Table 2). 
For example, from the core covariate-adjusted 
model, homocysteine concentrations were 
3.0% higher per IQR increment in patella Pb 
concentration (95% CI: 1.0, 5.0).
The association between an IQR increase 
in tibia Pb at baseline (14 μg/g) and homo-
cysteine (at baseline and follow-up) was 
substantially attenuated after adjustment for 
concurrent blood Pb (1.5% higher; 95% CI: 
–0.5, 3.6%), whereas there was little change 
in the association between an IQR increase in 
concurrent blood Pb and homo  cysteine (5.8% 
higher; 95% CI: 4.0, 7.6). These models were 
adjusted for the core covariates (time since 
baseline, baseline age, education level, smoking 
status, and BMI). Similarly, the association 
pertaining to patella Pb was attenuated, but the 
association pertaining to concurrent blood Pb 
changed very little when both were included in 
the same model. These findings are consistent 
with the results generated by the Baron–Kenny 
mediation procedure, in which the estimated 
effect of bone Pb (per IQR increment) on 
homocysteine mediated through blood Pb (i.e., 
the average causal mediation effect via blood 
Pb) was a 2.9% increase in homo  cysteine 
(95% CI: 2.0, 4.0); the average direct effect 
of bone Pb (per IQR increment) on homo-
cysteine via pathways other than blood Pb was 
1.7% (95% CI: –0.6, 4.3); and the estimated 
fraction of the total effect of bone Pb on 
homocysteine mediated by blood Pb was 0.63. 
Interaction between bone and blood Pb did 
not alter these findings.
Longitudinal changes in blood Pb in 
relation to changes in homocysteine. Similar 
to findings in the U.S. population during 
the study period, blood Pb concentration 
among study participants decreased over 
time, by 0.7 μg/dL, on average, per 3.5-year 
interval (range, –14 to 8 μg/dL). Among 
individuals with at least two visits (n = 747; 
1,245 observa  tions), the average time interval 
between visits was 3.9 years. Although homo-
cysteine concentration generally increased 
over time, the degree of change in homo-
cysteine generally tracked changes in blood Pb 
concentration. In particular, during intervals 
corresponding to the reference condition (i.e., 
never smoked, 67.5 years of age at the start of 
the interval, no change in blood Pb concentra-
tion, 1-year interval), homocysteine increased 
by 0.19 μmol/L, on average. By comparison, 
visit-to-visit intervals in which blood Pb 
concentrations declined corresponded to 
concomitantly smaller increases (or steeper 
declines) in homo  cysteine (p = 0.02). For 
each additional 1-μg/dL decline in blood 
Pb between visits, homo  cysteine concentra-
tion increased by 0.13 μmol/L less (95% CI: 
–0.25, –0.01). Although visit-to-visit increases 
Table 2. Adjusted percentage difference (95% CI) in plasma homocysteine per IQR increment in Pb 
exposure biomarker.
Estimate
Pb concentration
Blood  
(IQR = 3 μg/dL)
Tibia  
(IQR = 14 μg/g)
Patella  
(IQR = 21 μg/g)
Core modela
Observations (n) 1,056 (2,301) 777 (2,158) 770 (2,133)
Percentage difference in Hcy per IQR biomarker (95% CI) 6.3 (4.8, 7.8) 3.7 (1.7, 5.6) 3.0 (1.0, 5.0)
p-Value < 0.0001 0.0002 0.003
Core model plus plasma nutrientsb
Observations (n) 1,033 (2,240) 767 (2,106) 760 (2,082)
Percentage difference in Hcy per IQR biomarker (95% CI) 5.5 (4.0, 6.9) 3.6 (1.7, 5.5) 3.0 (1.0, 5.0)
p-Value < 0.0001 0.0002 0.003
Core model plus dietary and supplement nutrientsc
Observations (n) 779 (1,241) 634 (1,328) 627 (1,314)
Percentage difference in Hcy per IQR biomarker (95% CI) 6.5 (4.3, 8.8) 3.0 (0.8, 5.2) 2.1 (–0.2, 4.4)
p-Value < 0.0001 0.008 0.07
Hcy, homocysteine.
aCore covariates were baseline age, time since baseline, education, smoking status, alcohol consumption, and BMI; 
mixed-effects models used random intercepts and unstructured correlation structures. bAnalyses were further adjusted 
for plasma nutrients including core covariates and plasma PLP (B6), B12, and folate. cAnalyses were further adjusted for 
dietary nutrients including core covariates, total energy, and total energy–adjusted dietary intakes of vitamin B6, vitamin 
B12, and folate as well as supplement use (yes/no) of vitamin B6, vitamin B12, and folate, based on FFQ responses.Pb exposure and B vitamins influence homocysteine
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in blood Pb concentration were associated 
with greater increases in homocysteine 
(0.07 μmol/L greater increase in homocysteine 
per each additional 1-μg/dL increase in blood 
Pb), this result was not statistically significant 
(95% CI: –0.11, 0.25).
Baseline tibia Pb in relation to change 
in homocysteine. Although cumulative 
exposure to Pb, as measured by baseline 
tibia bone Pb concentration, was associated 
with higher plasma homocysteine over the 
course of follow-up (as reported above), it 
was not associated with the degree to which 
plasma homocysteine changed over time, 
as estimated by the cross-product term 
between tibia Pb and time since baseline 
(ptime–bone Pb inter  action = 0.9). Specifically, the 
estimated percentage difference in homocys-
teine per IQR increase in baseline tibia Pb 
(14 μg/g) was statistically consistent across 
visits: visit 1, 3.6% higher (95% CI: 1.4, 6.0); 
visit 2, 3.8% higher (95% CI: 1.2, 6.4); 
visit 3, 4.6% higher (95% CI: 1.7, 7.5); and 
visit 4, 5.5% higher (95% CI: 1.3, 9.9).
Association of blood Pb concentration 
with homocysteine, by intake of methyl-donor 
nutrients. The association between blood Pb 
concentration and concurrent plasma homo-
cysteine was significantly stronger among men 
whose dietary intakes of vitamin B6, folate, 
or vitamins B6, B12, and folate (combined) 
were below the median, even after adjusting 
for supplement use (Figure 2). For example, 
among men with lower vitamin B6 intake, an 
IQR increment in blood Pb level was associ-
ated with 8.7% higher homocysteine concen-
tration (95% CI: 6.0, 11.5%), compared 
with 2.0% higher (95% CI: –0.8, 5.0%) 
among men with higher vitamin B6 intake 
(pinter action = 0.0004). Associations between 
blood Pb and homocysteine also were signifi-
cantly stronger among men with lower dietary 
intakes of folate or of all three dietary nutri-
ents combined compared with men whose 
estimated intakes were equal to or above the 
median (pinter action = 0.02 and 0.003, respec-
tively); and among men with lower plasma 
folate, or men with lower plasma concentra-
tions of all three plasma nutrients combined, 
compared with men whose plasma concen-
trations were equal to or above the median 
(pinter action = 0.002 and 0.006, respectively). In 
addition, a pattern in which low folate intake 
conferred greater Pb-related homocysteine 
risk was present in the results of sensitivity 
analyses that a) incorporated supplement 
intake into the total intake, b) was restricted 
to supplement users, and c) compared users 
versus non  users of methyl-donor nutrient 
supplements (Figure 2). In these analyses, 
findings on other nutrients were less remark-
able. Secondary models were restricted to 
dietary intake of non  supplement users a) to 
reduce confounding by supplement use and 
its correlates; b) to reduce error in measure-
ment of total intake; and c) to limit the range 
of intakes to that which can be achieved via 
diet, especially in light of evidence-based 
scrutiny directed toward supplement use. 
We found evidence suggesting that the asso-
ciation between bone Pb and homocysteine 
varied by plasma and long-term dietary 
intake of vitamin B12 (pinter action-plasma 
= 0.00002; pinter action-diet = 0.1), but results 
were less suggestive with respect to folate 
(pinter action-plasma = 0.1; pinter action-diet = 0.8) 
or vitamin B6 (pinter action-plasma = 0.5; 
pinter action-diet = 0.1).
Figure 2. Adjusted percentage difference in homocysteine per IQR increment in blood Pb concentration by 
nutrient status level. All analyses were adjusted for age, education, alcohol consumption, smoking status, 
and BMI.
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Discussion
In this study of older men with community-
level exposure to Pb and typical dietary 
intakes, recent exposure to Pb, measured 
by blood Pb concentration, was positively 
associated with concurrent plasma homo-
cysteine concentration. This association was 
stronger among men with below-median 
dietary intakes of vitamins B6 and folate, 
and among men with below-median plasma 
folate. Homocysteine concentration among 
men in our study was comparable to that 
among similarly aged men in the general 
population (Jacques et al. 1999). The present 
study contains one of the richest available 
data collections on Pb exposure, diet, and 
homocysteine. It is strengthened by its use 
of both dietary and plasma measures of 
nutrient intake, and its repeated measures of 
homocysteine and blood Pb concentrations, 
in addition to its measures of cumulative 
Pb exposure, allowing detailed examination 
of differences and longitudinal changes in 
homocysteine with recent and cumulative 
Pb exposure.
In light of other homocysteine predictors, 
the magnitude of the association of Pb 
exposure with homocysteine is substantial. 
On average, homocysteine concentration 
was 6.3% higher per IQR (3 μg/dL) incre-
ment in blood Pb concentration, equivalent 
to the estimated increase in homocysteine 
over 5.5 years of follow-up (i.e., 5.5 years of 
aging), and about half of the estimated differ-
ence in homocysteine between current and 
never-smokers. In the Framingham Heart 
Study, a 25% increase in plasma homocys-
teine was associated with a 14% increase 
in the relative risk of incident Alzheimer’s 
disease over 8 years of follow-up (95% CI: 
6, 22%) (Seshadri et al. 2002), and a meta-
analysis of 30 retrospective or prospective 
studies estimated that a 25% increase in 
homo  cysteine (approximately 3 μmol/L) was 
associated with 11% increase in relative risk 
of ischemic heart disease (95% CI: 4, 17%) 
and a 19% increase in relative risk of stroke 
(95% CI: 5, 31%) (Homocysteine Studies 
Collaboration 2002). Overall, these findings 
suggest that, if the association between Pb 
and homocysteine is causal, a modest popu-
lation increase in homocysteine due to Pb 
exposure could dramatically increase the 
prevalence of cardiovascular and neurodegen-
erative diseases. Particularly in older adults, 
where bone turnover is relatively high and 
current exogenous exposure is generally low, 
the source of blood Pb may be bone resorp-
tion, which liberates historic Pb exposure.
Intakes of methyl-donor nutrients below 
the median for the study population appeared 
to strengthen the association between blood 
Pb and homocysteine. Among men with 
lower folate dietary intake, the estimated 
increase in homocysteine associated with 
an IQR increment of blood Pb was similar 
to the estimated increase in homocysteine 
over 9 years of follow-up, whereas among 
men with higher folate intake, the estimated 
increase was comparable to that associated 
with about 3 years of follow-up. We observed 
this disparity in blood Pb–homocysteine asso-
ciation by dietary nutrient intake, even after 
adjusting for supplement use or restricting to 
supplement non  users. These results are consis-
tent with the possibility that the additional 
nutrients found in foods may allow vitamins 
to work optimally (Lichtenstein and Russell 
2005), although we could not test this in our 
data. Thus, preventing Pb exposure may not 
only reduce the risk of elevated homocysteine, 
but among those who have been exposed, 
higher consumption of methyl-donor nutri-
ents may partially mitigate the influence of Pb 
on homocysteine.
Higher cumulative exposure to Pb, 
measured by concentrations in bone, also 
was associated with elevated homocysteine, 
but this association appeared to be attribut-
able, in large part, to recent Pb exposure. The 
problems specific to the analysis of discrete 
outcomes and/or mediators are not present in 
these analyses (Kaufman et al. 2004); assuming 
no inter  action and unmeasured confounding 
of the estimated blood Pb–homocysteine 
association (Cole and Hernan 2002; Kaufman 
et al. 2004), the results suggest that the influ-
ence of Pb exposure on homocysteine is fairly 
immediate and, thus, that recent exposure to 
Pb (measured in blood) may drive the associa-
tion between Pb and homocysteine. However, 
even with substantial cumulative exposure, 
interventions that minimize acute elevations 
in blood Pb concentration (e.g., from endog-
enous sources) may be an effective strategy to 
mitigate increases in homocysteine, although 
there is insufficient information to recommend 
such an intervention for this purpose at this 
time. Results from homocysteine-lowering 
dietary intervention trials among patients 
with prior disease are mixed: The interven-
tions effectively reduce circulating homocys-
teine but perform inconsistently in affecting 
homocysteine-related health outcomes 
(Mei et al. 2010; Morris 2012). Among the 
explanations for these inconsistent findings 
are that a) the study populations differed in 
their preintervention nutritional deficiencies, 
whereby supplementing deficiencies may help, 
but supplementing sufficient intake may have 
no effect or may cause harm (Morris 2012); 
b) the interventions may have begun too late 
to influence the health trajectory; or c) the 
observational associations of homocysteine 
with health outcomes may not be causal. Our 
study is among the first to evaluate whether 
the association between Pb exposure and 
homocysteine might be influenced by intake 
of folate and other B vitamins. In data from 
NHANES, the association between blood 
Pb concentration and homocysteine was 
more pronounced among people with below-
median plasma concentrations of vitamin 
B6 or folate than among people with higher 
plasma concentrations (pinter action = 0.002 and 
0.06, respectively). However, results for plasma 
vitamin B12 followed the opposite pattern, 
with a significantly stronger adverse association 
between blood Pb and homocysteine among 
those with higher vitamin B12 concentra-
tion (pinter action = 0.01) (Lee et al. 2012). In 
contrast, although our findings on vitamin 
B6 and folate were consistent with those from 
the NHANES study, our analyses of vitamin 
B12, whether based on reported intake or 
plasma concentration, yielded stronger asso-
ciations between blood Pb and homocysteine 
among those with lower vitamin B12 than 
among those with higher intakes, but these 
  interactions were not statistically significant.
Our finding that Pb exposure is associ-
ated with higher homocysteine concentration 
is consistent with previous epidemiological 
studies. Among workers occupationally exposed 
to Pb in Vietnam, blood Pb concentration and 
homocysteine were associated, although these 
analyses were not adjusted for any other factors 
(Chia et al. 2007). In a cross-sectional analysis 
of Baltimore Memory Study data from men 
(mean age, 59 years) with blood Pb and homo-
cysteine concentrations comparable to those 
in our participants, a 1.0-μg/dL increment in 
blood Pb was associated with a 0.43-μmol/L 
increase in homo  cysteine (Schafer et al. 2005). 
However, the investigators reported that there 
was no association between homocysteine and 
tibia Pb. By comparison, in the present study, 
a 1.0-μg/dL increment in blood Pb concentra-
tion was associated with a 0.30-μmol/L increase 
in homocysteine (95% CI: 0.23, 0.37). In 
NHANES participants (mean age, 50 years), 
homocysteine was higher across progressively 
increasing quartiles of blood Pb concentra-
tion, even though 95% of individuals had 
blood Pb concentration < 5 μg/dL (Lee et al. 
2012). In our study, 55% of participants had 
blood Pb concentration < 5 μg/dL at baseline. 
Among adults in Pakistan (18–60 years 
of age) with higher Pb concentration (mean 
blood Pb, 11.7 μg/dL), an IQR increase 
in blood Pb (8.3 μg/dL) was associated 
with 4.6% higher homo  cysteine (95% CI: 
2.6, 4.8%) (Yakub and Iqbal 2010). The asso-
ciation in the present study was larger: An IQR 
(3 μg/dL) increase in blood Pb   corresponded to 
6.3% higher homocysteine.
Our study has several limitations. Errors 
in the measurement of Pb exposures and 
homocysteine may have biased and/or reduced 
the precision of the associations we observed 
between the two. For example, the time of day 
of blood draw for homocysteine measurement Pb exposure and B vitamins influence homocysteine
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was not standardized, but homocysteine 
concentration follows a daily rhythm char-
acterized by an evening peak and nighttime 
low (Bonsch et al. 2007). In addition, plasma 
measures of homocysteine assess the pool of 
homocysteine released after reduction of all 
disulfide bonds in the sample. Total homo-
cysteine does not include homocysteine thio-
lactone (a product of mis  incorporation of 
homocysteine into proteins and subsequent 
error-editing) or homocysteine bound to 
protein by an amide bond (Perla-Kajan et al. 
2007). These homocysteine groups are poten-
tially toxic but might not be correlated with 
plasma homocysteine concentration (Perla-
Kajan et al. 2007).
It is possible that our observations reflect 
effects of Pb on kidney function. Lower kidney 
glomerular filtration rate (GFR) has been 
shown to increase homocysteine concentration 
in a prospective study of community-dwelling 
adults > 70 years of age (Lewerin et al. 2007). 
Chronic Pb exposure appears to contribute to 
chronic kidney disease, indicated by low GFR 
(Batuman et al. 1983; Brewster and Perazella 
2004; Muntner et al. 2003). In the NAS, 
for example, creatinine clearance was lower 
with higher long-term exposure to Pb, esti-
mated via patella Pb concentration (Wu et al. 
2003). Therefore, Pb exposure might influ-
ence homocysteine through an effect on renal 
function. We performed sensitivity analyses 
of blood Pb and homocysteine by further 
adjusting for creatinine clearance as a marker 
of kidney function, and as an intermediate in 
the above mechanism. Although the associa-
tion of blood Pb with homocysteine modestly 
decreased in magnitude (from a 6.3% increase 
in homocysteine per IQR increment in blood 
Pb, to a 5.5% increase), it remained positive 
and significant, indicating that Pb may elevate 
homocysteine independently of its renal effects. 
However, inferences about causal mechanisms 
should be interpreted with caution.
Some of our analyses had limited statis-
tical power. Missing nutrient data meant 
that sample sizes were smaller for analyses of 
Pb exposure, diet, and homocysteine. The 
change–change analyses also had limited 
power because participants were lost to 
follow-up over time. Finally, generaliz-
ability of our study may be limited because 
the study population was older, non-
Hispanic white men.
Conclusions
We found a significant positive association 
between blood Pb concentration and plasma 
homocysteine in a cohort of older men. This 
association between blood Pb and homocys-
teine was stronger than associations corre-
sponding to baseline bone Pb, and declines 
in blood Pb concentration over time corre-
sponded with smaller increases (or larger 
declines) in homocysteine over the same 
interval, suggesting that circulating Pb may 
influence circulating homocysteine through 
Pb’s influence on homocysteine metabolism, 
even at very low levels of Pb exposure. Our 
finding that the association between blood Pb 
and homocysteine was stronger among men 
with lower estimated intakes of methyl-donor 
nutrients—especially folate and vitamin B6—
suggests that nutrient intakes may influence 
susceptibility to the effects of Pb that might 
operate through effects on homocysteine. The 
associations of elevated homocysteine concen-
tration with cardiovascular and neurodegener-
ative diseases—along with the high prevalence 
of cumulative and now endogenous exposures 
to Pb in the population—suggest the poten-
tial public health value in researching joint 
interventions on diet and exposure to Pb.
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